Tango Therapeutics Announces Exceptional Phase 1/2 Results for Vopimetostat Combinations in Pancreatic Cancer
Key Highlights from the Clinical Report
- Remarkable Efficacy: The combination of vopimetostat (a PRMT5 inhibitor) and daraxonrasib (a RAS(ON) inhibitor from Revolution Medicines) demonstrated a 92% objective response rate (ORR) in metastatic pancreatic ductal adenocarcinoma (PDAC) patients with MTAP deletion and RAS mutation. For these patients, the 6-month progression-free survival (PFS) rate was 90%, and the disease control rate (DCR) reached 100%. In non-small cell lung cancer (NSCLC), the combination delivered a 100% ORR, though this was in a smaller cohort (3 patients, all responses confirmed).
- Durability & Tolerability: The clinical benefit appears durable, as most patients remained progression-free at 6 months. The combinations were generally well-tolerated, with no new safety signals and most adverse events rated as Grade 1 or 2. Dose-limiting toxicities (DLTs) were observed only at the higher dose level, and there were no discontinuations due to adverse events.
- Second Combination Data: Vopimetostat combined with zoldonrasib (another RAS(ON) inhibitor) in PDAC with MTAP deletion and KRAS G12D mutation showed a 52% ORR, a 74% 6-month PFS rate, and a 96% DCR. Safety profile remained favorable with no Grade 4/5 adverse events or DLTs.
- Development Plans: Based on these compelling results, Tango Therapeutics intends to rapidly advance the vopimetostat and daraxonrasib combination into Phase 3 development for first-line MTAP-deleted pancreatic cancer. A randomized-controlled Phase 3 trial is planned, subject to regulatory feedback, with additional opportunities to pursue registration in second-line settings.
- Broader Pipeline: Upcoming milestones include finalizing Phase 3 trial design, releasing vopimetostat lung cancer monotherapy data, and initial TNG456 glioblastoma data, all expected in the second half of 2026. Tango will also launch a Phase 1/2 vopimetostat + ERAS-0015 combination study and present further clinical data at scientific conferences.
- Market Opportunity: Vopimetostat targets MTAP-deleted cancers, which represent 10-15% of all human cancers, including approximately 40% of pancreatic cancer and 15% of lung cancer. These patient populations have significant unmet medical need, especially in pancreatic cancer, where chemotherapy is the current, often poorly tolerated, standard of care.
Investor-Relevant Details and Potential Share Price Impact
- Breakthrough Efficacy: The 92% ORR in heavily pre-treated, metastatic pancreatic cancer is unprecedented and far exceeds historical benchmarks for second- or third-line therapies. Such robust clinical activity, especially with high durability and tolerability, positions vopimetostat as a potential best-in-class targeted therapy.
- Accelerated Clinical Development: Advancement to Phase 3 in first-line MTAP-deleted PDAC signals confidence in the data, and if successful, could support a chemotherapy-free treatment option for patients. This significantly expands the addressable market and could materially increase Tango’s valuation.
- Safety Profile: No Grade 4/5 or dose-limiting toxicities at the main dose level and no discontinuations due to adverse events enhance the commercial viability of vopimetostat combinations.
- Upcoming Catalysts: Multiple data releases and trial initiations in the second half of 2026 provide near-term and mid-term inflection points for investors. Positive outcomes from the Phase 3 and additional monotherapy/combo trials could drive substantial upside for Tango’s shares.
- Risks and Uncertainties: The report emphasizes that initial results may not be replicated in future studies, and that Tango is reliant on third-party partners for clinical operations and drug supply. Regulatory risks, funding requirements, and broader market conditions (including government regulation) could impact timelines and commercialization.
Additional Information for Shareholders
- Conference Call: Tango Therapeutics will host a conference call to discuss these results with investors and analysts. The webcast will be available for replay for at least 30 days.
- Forward-Looking Statements: The company has explicitly stated that forward-looking statements are subject to risks and uncertainties, including clinical trial results, regulatory feedback, commercialization challenges, and potential delays.
Conclusion
These results mark a significant milestone for Tango Therapeutics and have the potential to materially impact the share price. The exceptional efficacy and safety profile of vopimetostat combinations, the planned rapid advancement to Phase 3, and multiple upcoming data releases represent substantial value drivers and key catalysts for investors. The possibility of a targeted, chemotherapy-free option for pancreatic cancer patients could redefine standards of care and expand market potential.
Disclaimer
This article contains forward-looking statements based on preliminary clinical data and Tango Therapeutics’ stated intentions. Actual results may differ due to regulatory, clinical, operational, or market risks. Investors should review Tango’s filings with the SEC and consult their financial advisors before making investment decisions. This article is for informational purposes only and does not constitute investment advice.
